In a report released today, Juan C. Sanabria from BMO Capital maintained a Buy rating on National Health Investors, with a price target of $90.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Juan C. Sanabria has given his Buy rating due to a combination of factors, including the positive financial performance of National Health Investors (NHI) in the third quarter of 2025. The company reported a significant beat in Funds Available for Distribution per share (FAD/sh), which exceeded expectations by 8 cents, despite some weaknesses in the Senior Housing Operating Portfolio (SHOP). This strong performance was primarily driven by deferrals, and as a result, the guidance for FAD/sh has been raised to reflect these results.
Furthermore, NHI’s normalized Funds from Operations per share (FFO/sh) also surpassed consensus estimates, showcasing a robust year-over-year growth. The company has made strategic acquisitions, amounting to $75 million at an 8% yield, which further supports its growth outlook. Despite some challenges in the SHOP segment, the overall financial health and strategic initiatives of NHI have led Juan C. Sanabria to maintain a positive outlook on the stock, justifying the Buy rating.
C. Sanabria covers the Real Estate sector, focusing on stocks such as Brixmor Property, National Health Investors, and Ventas. According to TipRanks, C. Sanabria has an average return of 0.5% and a 45.73% success rate on recommended stocks.
In another report released on October 31, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $85.00 price target.